Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Rises By 152.8%

Biofrontera Inc. (NASDAQ:BFRI) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 61,079 shares, a growth of 152.8% from the July 15th total of 24,157 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 359,826 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC lifted its stake in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 at the end of the most recent reporting period. Institutional investors own 10.08% of the company’s stock.

Biofrontera Stock Performance

Biofrontera stock opened at $1.26 on Friday. The company’s 50-day moving average price is $1.07 and its 200-day moving average price is $0.98. The company has a quick ratio of 1.09, a current ratio of 1.20 and a debt-to-equity ratio of 0.78. The company has a market cap of $16.13 million, a PE ratio of -1.30 and a beta of 0.78. Biofrontera has a twelve month low of $0.55 and a twelve month high of $1.40.

Biofrontera (NASDAQ:BFRI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. On average, equities research analysts forecast that Biofrontera will post -0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on BFRI. Wall Street Zen upgraded Biofrontera to a “hold” rating in a report on Saturday, July 18th. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Biofrontera currently has a consensus rating of “Hold”.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.